TAAR1 ligands

A compound of formula

• wherein
• R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen,
• —O—(CH2)p-aryl or aryl;
• o is 2;
• and one R2 is NR′R″ and the other R2 is halogen, wherein
• R′ and R″ together with the N atom to which they are attached form a piperazine group optionally substituted by lower alkyl, —CH2-cycloalkyl,
• —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy;
• W is phenyl, benzo[1,3]dioxolyl, pyridine-2, 3- or 4-yl, indolyl or cycloalkyl;
• L is —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)— or —CH2CH2CH2—;
• X is N;
• n is 1 or 2;
• in case n is 2, each R1 can be the same or different;
• and
• p is 0, 1, 2 or 3;
• or a pharmaceutically suitable acid addition salt thereof.

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula IA

• wherein
• R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen,
• —O—(CH2)p-aryl or aryl;
• R′R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2- cycloalkyl, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy;
• W is phenyl, benzo[1,3]dioxolyl, pyridine-2, 3- or 4-yl, indolyl or cycloalkyl;
• L is —CH2—, —CH(CH3)—, —CH2CH2—, or —CH2CH(CH3)—;
• X is N;
• n is 1 or 2;
• in case n is 2, each R1 can be the same or different;
• o is 1;
• and
• p is 0, 1, 2 or 3;
• or a pharmaceutically suitable acid addition salt thereof, with the exception of the following compound
• 6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide,
• and a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I

• wherein
• R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen,
• —O—(CH2)p-aryl or aryl;
• o is 2;
• and one R2 is NR′R″ and the other R2 is halogen, wherein
• R′ and R″ together with the N atom to which they are attached form a piperazine group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy;
• W is phenyl, benzo[1,3]dioxolyl, pyridine-2, 3- or 4-yl, indolyl or cycloalkyl;
• L is —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)— or —CH2CH2CH2—;
• X is N;
• n is 1 or 2;
• in case n is 2, each R1 can be the same or different;
• and
• p is 0, 1, 2 or 3;
• or a pharmaceutically suitable acid addition salt thereof
• and a pharmaceutically acceptable carrier.